Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1954 1
1961 1
1985 1
1986 9
1987 7
1988 20
1989 12
1990 19
1991 24
1992 29
1993 53
1994 50
1995 52
1996 53
1997 67
1998 51
1999 78
2000 73
2001 61
2002 68
2003 64
2004 89
2005 96
2006 118
2007 120
2008 116
2009 119
2010 118
2011 123
2012 114
2013 131
2014 155
2015 132
2016 106
2017 114
2018 124
2019 119
2020 115
2021 117
2022 111
2023 114
2024 129
2025 108
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,066 results

Results by year

Filters applied: . Clear all
Page 1
Zolpidem for the Management of Catatonia: A Systematic Review.
Gunther M, Tran N, Jiang S. Gunther M, et al. J Acad Consult Liaison Psychiatry. 2025 Jan-Feb;66(1):49-56. doi: 10.1016/j.jaclp.2024.10.004. Epub 2024 Nov 9. J Acad Consult Liaison Psychiatry. 2025. PMID: 39522949
In total, 28 out of the 35 reported cases of catatonia (80%) responded positively to zolpidem. CONCLUSIONS: An 80% positive response rate for zolpidem in lysing catatonia is encouraging but may be an overestimate due to reporting bias of case-level data. Results may …
In total, 28 out of the 35 reported cases of catatonia (80%) responded positively to zolpidem. CONCLUSIONS: An 80% positive response …
Zolpidem extended-release.
Moen MD, Plosker GL. Moen MD, et al. CNS Drugs. 2006;20(5):419-26; discussion 427-8. doi: 10.2165/00023210-200620050-00006. CNS Drugs. 2006. PMID: 16696581 Clinical Trial.
Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is indicated in the US for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Zolpidem C …
Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is i …
Zolpidem-induced psychosis.
Markowitz JS, Brewerton TD. Markowitz JS, et al. Ann Clin Psychiatry. 1996 Jun;8(2):89-91. doi: 10.3109/10401239609148806. Ann Clin Psychiatry. 1996. PMID: 8807033
Zolpidem is reported to be a safe and effective hypnotic agent for the short-term treatment of insomnia. ...All were female, there appeared to be some dose dependency involved, and the adverse event resolved fairly quickly upon zolpidem discontinuation. Zolpidem …
Zolpidem is reported to be a safe and effective hypnotic agent for the short-term treatment of insomnia. ...All were female, there ap …
Zolpidem for insomnia.
Greenblatt DJ, Roth T. Greenblatt DJ, et al. Expert Opin Pharmacother. 2012 Apr;13(6):879-93. doi: 10.1517/14656566.2012.667074. Epub 2012 Mar 19. Expert Opin Pharmacother. 2012. PMID: 22424586 Review.
INTRODUCTION: The imidazopyridine derivative zolpidem , which acts as a benzodiazepine (BZ) receptor agonist, is the most widely prescribed hypnotic drug in the US. ...Hypnotic efficacy is maintained with repeated nightly use, and the risk of rebound insomnia is low. Depen …
INTRODUCTION: The imidazopyridine derivative zolpidem , which acts as a benzodiazepine (BZ) receptor agonist, is the most widely pres …
Zolpidem-induced sleep-driving.
Doane JA, Dalpiaz AS. Doane JA, et al. Am J Med. 2008 Nov;121(11):e5. doi: 10.1016/j.amjmed.2008.04.035. Am J Med. 2008. PMID: 18954831 No abstract available.
Iatrogenic zolpidem dependence.
Bhatia MS, Kohli GS. Bhatia MS, et al. J Neuropsychiatry Clin Neurosci. 2014 Apr 1;26(2):E38. doi: 10.1176/appi.neuropsych.13040094. J Neuropsychiatry Clin Neurosci. 2014. PMID: 24763787 No abstract available.
Novel zolpidem formulations.
Owen RT. Owen RT. Drugs Today (Barc). 2009 May;45(5):395-400. doi: 10.1358/dot.2009.45.5.1370457. Drugs Today (Barc). 2009. PMID: 19584967 Review.
Zolpidem is currently the global market leader in the hypnotic arena. Recently several novel zolpidem formulations have been launched in the U.S. or are in the preregistration development phase. ...
Zolpidem is currently the global market leader in the hypnotic arena. Recently several novel zolpidem formulations have been l …
Zolpidem's use for insomnia.
Monti JM, Spence DW, Buttoo K, Pandi-Perumal SR. Monti JM, et al. Asian J Psychiatr. 2017 Feb;25:79-90. doi: 10.1016/j.ajp.2016.10.006. Epub 2016 Oct 12. Asian J Psychiatr. 2017. PMID: 28262178 Review.
Zolpidem is a short-acting non-benzodiazepine hypnotic drug that belongs to the imidazopyridine class. ...Sublingual zolpidem-LD (5mg) and zolpidem oral spray are indicated for middle-of-the-night (MOTN) wakefulness and difficulty returning to sleep, while su …
Zolpidem is a short-acting non-benzodiazepine hypnotic drug that belongs to the imidazopyridine class. ...Sublingual zolpidem- …
Advances in Z-drug detection.
Al S, Kul A, Sagirli O. Al S, et al. Clin Chim Acta. 2025 Jun 15;574:120329. doi: 10.1016/j.cca.2025.120329. Epub 2025 Apr 25. Clin Chim Acta. 2025. PMID: 40288554 Review.
The use of Z-drugs (zolpidem, zaleplon, zopiclone, and eszopiclone) has increased in recent years, leading to a growing need for analytical methods to accurately and reliably detect these compounds in biological samples. ...
The use of Z-drugs (zolpidem, zaleplon, zopiclone, and eszopiclone) has increased in recent years, leading to a growing need for anal …
EEG dynamics induced by zolpidem forecast consciousness evolution in prolonged disorders of consciousness.
Gao Q, Hao J, Kang X, Yuan F, Liu Y, Chen R, Liu X, Li R, Jiang W. Gao Q, et al. Clin Neurophysiol. 2023 Sep;153:46-56. doi: 10.1016/j.clinph.2023.06.012. Epub 2023 Jul 1. Clin Neurophysiol. 2023. PMID: 37454563 Free article.
OBJECTIVE: To explore whether the EEG dynamics induced by zolpidem can predict consciousness evolution in patients with prolonged disorders of consciousness (PDOC). ...CONCLUSIONS: Our work revealed that the specific EEG responses to zolpidem can predict consciousne …
OBJECTIVE: To explore whether the EEG dynamics induced by zolpidem can predict consciousness evolution in patients with prolonged dis …
3,066 results